BACKGROUND: Insulin-like growth factors (IGFs) are anabolic proteins that are essential regulators of cell division, differentiation and growth. We describe the longitudinal changes in IGF-I, IGF-II and the binding proteins IGFBP-1, -2 and -3 before and during normal pregnancy. METHOD: Serum samples were taken before conception and then at 12, 24 and 36 weeks of gestation in 41 healthy women with uncomplicated pregnancies. We measured IGF-I using an automated chemiluminescent method, IGF-II and IGFBP-2 using in-house radioimmunoassays (RIAs), and IGFBP-1 and IGFBP-3 using commercial enzyme-linked immunosorbent assay (ELISA) and RIA kits, respectively. Because of the potential haemodilution effects during pregnancy, albumin was also measured in all samples. RESULTS: There was a significant fall in IGF-I during the first (36%) and second trimesters (21%) followed by an increase of 25% at 36 weeks. During pregnancy, the mean IGF-II concentrations fell by 12% at 12 weeks, 8% at 24 and 8% at 36 weeks compared with pre-conception values. When IGF-II results were adjusted for the haemodilution of pregnancy, its concentrations increased. During pregnancy, there was a rapid increase in mean IGFBP-1 levels by 17-fold (12 weeks), 24-fold (24 weeks) and 25-fold (36 weeks). IGFBP-2 concentrations fell after conception but started to increase towards term. This increase was more significant when adjusted for haemodilution. In contrast, IGFBP-3 concentrations increased significantly throughout pregnancy. CONCLUSION: Our data on the physiological changes of IGFs and their binding proteins add further evidence of the vital roles of these hormones throughout normal pregnancy.
BACKGROUND: Insulin-like growth factors (IGFs) are anabolic proteins that are essential regulators of cell division, differentiation and growth. We describe the longitudinal changes in IGF-I, IGF-II and the binding proteins IGFBP-1, -2 and -3 before and during normal pregnancy. METHOD: Serum samples were taken before conception and then at 12, 24 and 36 weeks of gestation in 41 healthy women with uncomplicated pregnancies. We measured IGF-I using an automated chemiluminescent method, IGF-II and IGFBP-2 using in-house radioimmunoassays (RIAs), and IGFBP-1 and IGFBP-3 using commercial enzyme-linked immunosorbent assay (ELISA) and RIA kits, respectively. Because of the potential haemodilution effects during pregnancy, albumin was also measured in all samples. RESULTS: There was a significant fall in IGF-I during the first (36%) and second trimesters (21%) followed by an increase of 25% at 36 weeks. During pregnancy, the mean IGF-II concentrations fell by 12% at 12 weeks, 8% at 24 and 8% at 36 weeks compared with pre-conception values. When IGF-II results were adjusted for the haemodilution of pregnancy, its concentrations increased. During pregnancy, there was a rapid increase in mean IGFBP-1 levels by 17-fold (12 weeks), 24-fold (24 weeks) and 25-fold (36 weeks). IGFBP-2 concentrations fell after conception but started to increase towards term. This increase was more significant when adjusted for haemodilution. In contrast, IGFBP-3 concentrations increased significantly throughout pregnancy. CONCLUSION: Our data on the physiological changes of IGFs and their binding proteins add further evidence of the vital roles of these hormones throughout normal pregnancy.
Authors: Helena Schock; Renée T Fortner; Heljä-Marja Surcel; Kjell Grankvist; Eero Pukkala; Matti Lehtinen; Eva Lundin Journal: Int J Cancer Date: 2014-12-17 Impact factor: 7.396
Authors: Tianhui Chen; Eva Lundin; Kjell Grankvist; Anne Zeleniuch-Jacquotte; Marianne Wulff; Yelena Afanasyeva; Helena Schock; Robert Johansson; Per Lenner; Goran Hallmans; Goran Wadell; Paolo Toniolo; Annekatrin Lukanova Journal: Cancer Causes Control Date: 2010-01-19 Impact factor: 2.506
Authors: Sven Cnattingius; Sandra Eloranta; Hans-Olov Adami; Ove Axelsson; Paul W Dickman; Chung-cheng Hsieh; Lorelei A Mucci; Dimitrios Trichopoulos; Mats Lambe; Anna L V Johansson Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-09 Impact factor: 4.254
Authors: Tianhui Chen; Annekatrin Lukanova; Kjell Grankvist; Anne Zeleniuch-Jacquotte; Marianne Wulff; Robert Johansson; Helena Schock; Per Lenner; Goran Hallmans; Goran Wadell; Paolo Toniolo; Eva Lundin Journal: Breast Cancer Res Treat Date: 2009-09-02 Impact factor: 4.872
Authors: K L Gatford; G K Heinemann; S D Thompson; J V Zhang; S Buckberry; J A Owens; G A Dekker; C T Roberts Journal: Endocr Connect Date: 2014-08-12 Impact factor: 3.335
Authors: Kirsten Mense; Julia Heidekorn-Dettmer; Elisa Wirthgen; Yette Brockelmann; Ralf Bortfeldt; Sarah Peter; Markus Jung; Christine Höflich; Andreas Hoeflich; Marion Schmicke Journal: Front Endocrinol (Lausanne) Date: 2018-06-12 Impact factor: 5.555
Authors: Eva Pericuesta; Julia L Gutiérrez-Arroyo; Maria J Sánchez-Calabuig; Alfonso Gutiérrez-Adán Journal: Int J Mol Sci Date: 2021-04-01 Impact factor: 5.923